Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-001	May 12, 2021		DISCN	Yes	No	10,898,575	⤷ Start Trial	Y			⤷ Start Trial
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-002	May 12, 2021		RX	Yes	Yes	10,632,199	⤷ Start Trial	Y			⤷ Start Trial
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-003	May 12, 2021		DISCN	Yes	No	10,098,957	⤷ Start Trial				⤷ Start Trial
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-004	May 12, 2021		RX	Yes	Yes	9,913,909	⤷ Start Trial				⤷ Start Trial
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-001	May 12, 2021		DISCN	Yes	No	11,413,350	⤷ Start Trial				⤷ Start Trial
Heron Theraps Inc	ZYNRELEF KIT	bupivacaine; meloxicam	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	211988-001	May 12, 2021		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 30, 2026

Local anesthesia is a therapeutic function, not a single drug. The patent landscape is therefore fragmented across active ingredients (lidocaine, bupivacaine, ropivacaine, mepivacaine, articaine, benzocaine, prilocaine, tetracaine), delivery systems (injectables, topical gels/creams/patches, liposomal depots), and use claims (local infiltration, peripheral nerve block, epidural/spinal, dental). Market dynamics track procedure volumes and reimbursement, while patent risk depends on whether the reference product is protected by formulation, method-of-use, or device-adjacent IP beyond the core composition.

Which local anesthetics dominate U.S. demand and what drives price versus volume?

Local anesthetics are widely generic, but differentiated products exist in select segments: long-acting bupivacaine/ropivacaine depots, bupivacaine liposome products, and site-specific/topical formulations. Pricing power is most durable where claims cover extended duration, controlled release, or specific clinical protocols.

Key commercial dynamics by site of use

Dental: Lidocaine and articaine products dominate outpatient procedures; formulation and concentration differentials matter, but many actives are generic.
Orthopedics and ambulatory surgery: Peripheral nerve blocks drive demand for longer-acting amide anesthetics (bupivacaine, ropivacaine) and adjuvant platforms.
Pain management and anesthesia care settings: Epidural/spinal use supports strong demand for branded long-acting options, especially where dosing accuracy and onset/offset profiles are protected.
Dermatology and minor procedures: Benzocaine and lidocaine topical products are competitive, with patents concentrated in specific delivery systems and barrier technologies.

Competitive structure

Most actives: Composition-of-matter is typically expired or near-expired for older molecules.
Brands persist where:
- a controlled-release or depot technology is patented,
- combination or method-of-use claims persist, or
- device-delivery constraints limit easy AB switching.
Reimbursement: Many payers prefer lower-cost generics unless clinical advantage is captured by trial endpoints (duration of analgesia, reduced opioid use, reduced block “wear-off” rates).

What patents protect local anesthetics in 2026: composition, formulation, method of use, and depot technologies?

In practice, “local anesthesia” protection concentrates in four buckets.

1) Composition-of-matter and early-era molecule patents

For classical local anesthetics (lidocaine, bupivacaine, ropivacaine, mepivacaine, articaine, benzocaine, prilocaine, tetracaine), most composition patents from the 1960s to 1990s are expired. The current playbook is therefore:

formulation IP,
process IP (manufacturing),
device or delivery-system claims, and
method-of-use claims aligned with dosing regimens or surgical indications.

2) Formulation patents that extend duration or improve tolerability

Common IP themes:

controlled release (micro/nanoparticles, polymeric matrices, liposomes),
reduced burst release,
altered pH or solubilization,
preservative-free formats,
needle-friendly viscosity and spray/gel performance,
compatibility with epinephrine or other co-administered agents.

3) Method-of-use and dosing-regimen patents

Typical claim structures:

specific block types (e.g., peripheral nerve block variants),
timing of administration relative to surgery,
dose ranges and titration rules,
patient selection criteria (still framed as method claims rather than biomarkers).

4) Process and manufacturing patents

For depots, the hardest barriers often are:

manufacturing steps that define particle size distribution, encapsulation efficiency, or liposome stability,
sterilization and shelf-life processes,
scale-up parameters.

These patents can matter even when the active is generic because an ANDA must show bioequivalence to the reference but does not necessarily “free-ride” past manufacturing claims if they are asserted as method/process.

Which local anesthetic patent estates remain active and where are the biggest generic barriers?

The highest-resilience estates are associated with:

long-acting depot bupivacaine (liposomal depots),
long-acting amide anesthetics in specialized delivery,
select topical extended-duration technologies,
combinations with adjuvants where claims exist for a specific clinical protocol.

Depot and controlled-release: where exclusivity usually concentrates

Liposomal bupivacaine (depot platform)
Risk profile: generic entry is constrained by the ability to replicate extended-release behavior, not only API concentration.
Polymer or microsphere depots
Risk profile: process and particle-engineering patents can be more difficult than formula swaps.
Transdermal or adhesive technologies
Risk profile: formulation plus device adherence mechanics can create non-trivial AB switching friction.

Topical local anesthetics: where patents still matter

Extended-duration gels/patches with controlled release
Barrier formulations (skin permeation modifiers)
Preservative-free and specific viscosity systems

Injectable anesthetics without depots

If the product is a conventional injectable, the core molecules are usually generic. Residual IP typically sits in:

packaging configurations,
specific concentration combinations,
clinical protocol claims (where enforceable).

When does local anesthesia exclusivity end: how do patent expiry and FDA exclusivity interact for injectable and topical products?

Local anesthesia exclusivity depends on both:

patent term (composition, formulation, method, process), and
regulatory exclusivity (Hatch-Waxman and pediatric exclusivity, orphan if applicable, and new chemical entity timelines where relevant).

Practical rule: patents dictate generic timing even after FDA exclusivity fades

Most local anesthetics are not “new chemical entities” in the modern sense.
The limiting factor is usually a listed patent in the FDA Orange Book (for small molecules) and then any unexpired method-of-use or formulation claims.

Launch timing mechanics

Generic applicants time:
- when Orange Book patents expire,
- when any statutory exclusivity ends,
- and whether a Paragraph IV notice triggers an automatic 30-month stay.
The generic outcome is typically binary:
- If the litigated patent is invalid or not infringed, entry accelerates.
- If the branded patent is upheld, entry is blocked until final resolution or settlement.

What is the Orange Book status for local anesthetics: which patents are listed and how does that shape Paragraph IV risk?

The Orange Book lists patent numbers tied to an approved NDA/ANDA product for which a generic sponsor must address each listed patent. For local anesthetics, the most common “listed” patents still active into the 2020s tend to be:

depot or controlled release formulation patents,
method-of-use for specific anesthesia techniques,
and sometimes device-related packaging patents.

Generic entry risk is driven by:

the count of listed patents,
claim scope (broader method vs narrow composition),
and enforcement posture (how many patents are asserted in litigation).

Featured snippet answer

For local anesthetic products with a meaningful residual IP moat, the Orange Book typically shows a concentrated set of formulation and/or method-of-use patents; these are the patents that drive Paragraph IV litigation and settlement timing.

What Paragraph IV challenges exist for long-acting local anesthetic depots and how do settlements affect launch dates?

For depot-style local anesthetics, Paragraph IV filings are common once a generic believes it can avoid infringement by:

changing release mechanism,
using a different depot architecture,
or asserting non-infringement by clinical/protocol separation.

Settlement patterns that matter commercially

Early settlements reduce litigation costs but can lock in branded entry prevention through:
- agreed “design-around” dates,
- delayed launch dates,
- and licensing terms.
Late settlements occur when claim construction narrows the pathway for generic design changes.

Business impact

Settlements shape:

when generics become price benchmarks,
when hospitals switch formularies,
and how soon biosimilar-style competitive pressure would arrive (even though these are not biologics).

How does local anesthetic patent strength compare across lidocaine, bupivacaine, ropivacaine, and articaine?

Because older molecules are widely generic, “strength” is not comparable by composition patents. Strength is mainly comparable by:

whether the marketed product is a depot or controlled-release version with active IP, and
whether there are enforceable method-of-use claims tied to clinical protocols.

Relative strength snapshot (IP-driven, not chemistry-driven)

Lidocaine: Mostly generic, residual strength in topical delivery systems and select preservative-free or extended-duration formats.
Bupivacaine: Strongest current differentiation when paired with long-acting depot technologies.
Ropivacaine: Often generic at conventional concentrations, residual strength in long-acting formats and specific clinical protocols where patented.
Articaine: Generally generic across many indications, fewer high-value residual patents except where formulation or delivery is protected.

What formulations are protected for local anesthesia: gels, creams, sprays, patches, and liposomal injectables?

Protection concentrates in two product performance dimensions:

Drug release profile (burst vs sustained)
Patient experience and administration (viscosity, adhesion, needle compatibility)

Injectable depots (highest IP density)

Liposomal or polymer-based bupivacaine depots
Injectable microspheres
Extended-release matrices

Topicals

Viscous gels and creams that modulate permeation
Adhesive patches with controlled drug delivery
Spray formulations with standardized dosing volumes

Key infringement logic for generics

Generic sponsors must show:

sameness of active concentration and dosage form per ANDA standards, and
bioequivalence where required. But litigation can still hinge on formulation-level claim language:
“sustained release for X hours” constraints,
particle size or encapsulation parameters,
depot structure defined by preparation process.

What method-of-use patents exist for local anesthesia and how do they affect generic design-around?

Method-of-use claims affect generics even where formulation is weak, because the branded sponsor can argue infringement when:

the generic product is prescribed and used in a patented protocol, even if the generic labels differ slightly.

Common claim targets

Specific timing: before incision vs after incision
Specific technique: nerve block type and distribution
Dose ranges: mg/kg and maximum limits
Combination use patterns: co-administration with epinephrine or other anesthetic techniques where claims exist

Commercial consequence

Even if a generic wins on formulation, it can still face:

labeling carve-outs and “skin in the game” litigation over physician instructions,
settlement constraints on indicated use.

How does local anesthesia delivery device packaging affect patent risk?

While local anesthetic active molecules are usually easy to substitute, device and packaging patents can matter when they:

enable unique administration mechanics,
define mixing systems (for multi-component combinations),
include needle-free delivery or specialized applicators that enable performance claims.

Device-adjacent patents can also function as weak but useful litigation leverage when the branded sponsor can point to a “substantially different” administration experience tied to claim language.

What generic entry risks exist for local anesthesia products with multiple listed patents?

For depot and controlled-release products, the generic entry risk usually rises with:

a larger list of Orange Book patents,
presence of method-of-use claims,
and active process/manufacturing claims that complicate design-around.

Generic decision tree (market-facing)

If the product is conventional injectable or generic topical: risk is lower; generics enter quickly once patents expire.
If the product is controlled-release depot: risk is higher; generics either settle for delay or enter with design-around and label restrictions.

Which companies are active in challenging local anesthetic patents?

Local anesthetic litigation tends to mirror the broader H-Farma landscape:

generics: firms filing ANDAs with Paragraph IV notices,
branded: originators and branded product subsidiaries,
litigation support: generic litigators that specialize in claim construction and depot/formulation invalidity.

Because the local anesthesia category is broad, the relevant company list is product-specific and often changes with each depot platform.

Patent expiration dates for local anesthetics: what drives the next wave of generic switching?

The next wave is driven by:

remaining life of depot/formulation patents,
end of pediatric exclusivity where applicable,
expiration of method-of-use patents that remain listed in the Orange Book.

Timeline framework (how markets price it)

Pre-expiration (18-36 months): generic filings increase, Paragraph IV notices appear.
30-month stay window: branded can maintain price until litigation ends or settles.
Post-expiration: the winner is often the first successful ANDA filer with favorable label and formulary access.

How does local anesthesia patent strategy vary between branded originators and reformulators?

Branded originators tend to:

build a multi-patent chain around controlled release and method-of-use. Reformulators and follow-on sponsors tend to:
focus on narrower formulation improvements and “newness” around delivery format,
pursue faster regulatory pathways when actives are already approved.

The practical outcome:

originators dominate the longest duration products,
reformulators compete on convenience, tolerability, and packaging, not on depot architecture.

Key Takeaways

Local anesthesia is an IP mosaic across actives, delivery systems, and clinical techniques; most older molecules are generic, while residual patent value sits in depot/control-release formulations and enforceable method-of-use claims.
Generic timing is driven by the Orange Book patent list and Paragraph IV litigation posture, not by the broad therapeutic category.
The highest barriers are controlled-release depots where formulation structure and manufacturing/process claims complicate design-around.
Market dynamics track procedural volumes, ambulatory surgery growth, and payer formulary behavior that responds to extended-duration claims and evidence of reduced re-dosing.

FAQs

How many Orange Book patents typically block generic entry for long-acting bupivacaine depots?
What labeling and dosing changes can a generic make to avoid infringing local anesthesia method-of-use patents?
Do controlled-release local anesthetic patents focus more on composition or manufacturing process?
How does a Paragraph IV settlement change hospital formulary outcomes for local anesthetics?
Which local anesthetic delivery formats have the highest patent density: injectables, patches, or topical gels?

References

U.S. FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
35 U.S.C. § 156 (Patent term extension). U.S. Government Publishing Office.
21 U.S.C. § 355 (Hatch-Waxman Amendments). U.S. Government Publishing Office.